# Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension

Study · id `cardio:ct-nct02203916` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02203916](<https://clinicaltrials.gov/study/NCT02203916>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02203916

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 328 participants.

## Technical summary

Registry record NCT02203916. Randomized; quadruple masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2016-12-19.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 328 participants (enrolled count; ClinicalTrials.gov record NCT02203916, source copy `cardio:ctgov-nct02203916-2016-12-19`, retrieved 2026-10-26)
- Start date: 2014-07 (registry gives no type) (ClinicalTrials.gov record NCT02203916, source copy `cardio:ctgov-nct02203916-2016-12-19`, retrieved 2026-10-26)
- Primary completion: 2016-01 (actual) (ClinicalTrials.gov record NCT02203916, source copy `cardio:ctgov-nct02203916-2016-12-19`, retrieved 2026-10-26)
- Completion: 2016-02 (actual) (ClinicalTrials.gov record NCT02203916, source copy `cardio:ctgov-nct02203916-2016-12-19`, retrieved 2026-10-26)
- Results first posted: 2016-12-19 (ClinicalTrials.gov record NCT02203916, source copy `cardio:ctgov-nct02203916-2016-12-19`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02203916, source copy `cardio:ctgov-nct02203916-2016-12-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02203916-2016-12-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension
- Condition: Hypertension
- Intervention (Drug): Azilsartan medoxomil
- Intervention (Drug): Azilsartan medoxomil placebo
- Lead sponsor: Takeda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Takeda (`cardio:org-takeda`)

## Provenance

Content hash: d3966b7f291094dcc54dd9c55e27d61101e8dff3d032f86c21c913ae7fd5ec0e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
